Rheumatoid Arthritis eJournal Club
   

Safety of Novel Immunomodulatory Therapies

Print this Content
 
Release Date:  March 10, 2009 Renewal Date:  March 10, 2010 Expiration Date:  September 10, 2010

Technical Requirements
(will appear in new window)
 
Estimated Time of Completion 1 hour
Description / Overview The purpose of this activity is to consider safety issues concerning tumor necrosis factor (TNF) inhibitors as they relate to a patient with rheumatoid arthritis (RA) who is considering treatment with a TNF inhibitor for the first time.
Objectives At the conclusion of this activity, the participant will be able to:
  1. Discuss with a patient potential safety issues related to the use of TNF inhibitors.
  2. Describe target- and agent-related safety issues associated with the use of TNF inhibitors.
  3. Outline a patient management strategy for the use of TNF inhibitors to optimize therapy while balancing their potential risks.
Target Audience This activity is directed to rheumatologists and primary care physicians who treat patients with RA.
Accreditation The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Director Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Vice Chairman
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, Ohio
Author / Faculty Arthur Kavanaugh, MD
Professor of Medicine
Division of Rheumatology, Allergy, and Immunology
Director, Center for Innovative Therapy
University of California, San Diego
School of Medicine
San Diego, California
Faculty Disclosure In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty has indicated that he may have a relationship which, in the context of his presentation, could be perceived as a potential conflict of interest:

Leonard Calabrese, DO
  Consulting: Abbott Laboratories;
Elan Pharmaceuticals, Inc.;
Genentech, Inc.; Roche Laboratories, Inc.
 
  Teaching and Speaking: Genentech, Inc.

The following faculty member has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest:

Arthur Kavanaugh, MD

The Cleveland Clinic Foundation Center for Continuing Education
acknowledges educational grants for partial support of this activity from:

Bristol – Myers Squibb Company, Genentech/Biogen Idec

Wyeth Pharmaceuticals

This CME activity was produced by The Cleveland Clinic Foundation Center for Continuing Education and DIME.

CME Disclaimer